Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock.

Various clinical trials targeting different parts of the inflammatory response have failed to reach significance with regard to their primary endpoints. 46 However, in the COMplement inhibition in Myocardial infarction treated with Angioplasty trial, 47 where complement inhibition with the C5‐inhibitor pexelizumab was given as a bolus dose and with continuous infusion for 20 h following MI, a significant reduction in 90 day mortality was seen.

also in 4,113 other papers